Kite Pharma, part of Gilead Sciences, has announced that it will build a 6.000 square meters facility at its Oceanside, California, biologics site just for developing viral vectors, the tools needed to deliver genetic material into cells. So far, Kite has been buying from contractors the viral vector, material needed for its CAR-T treatment Yescarta and for the novel cell therapies, like KTE-X19, whose dossier will be submitted to the Regulatory Authorities within this year